Mentioned:
Moderna and Merck want to change the future of personalized cancer treatments. And now, they’ve just delivered potential breakthrough results from their Phase III clinical trial.
What’s happening:
- Moderna (NASDAQ: MRNA) and Merck (NYSE: MRK) have publicly stated they've achieved a positive Phase III readout for their personalized cancer vaccine
Why it matters:
- This is the first time ever that a personalized cancer vaccine has shown a statistical significant reduction in melanoma recurrence risk versus standard treatment in a Phase III clinical trial
Going deeper:
- Moderna and Merck co-developed intismeran autogene as a personalized mRNA cancer therapy that is custom built from each patient’s own tumour mutations to train the immune system to attack the cancer
- Moderna and Merck will continue to advance intismeran autogene through their Phase III clinical trial and deliver overall survival data as well as full efficacy results imminently
The fine print:
- Merck and Moderna have not yet publicly disclosed hazard ratios or full patient data from their Phase III clinical trial
Market reaction:
- Shares of Moderna surged more than +80% following the Phase III readout announcement
